Sensorion SA (EPA:ALSEN)
France · Delayed Price · Currency is EUR 0.4180
-0.0120 (-2.79%)
May 14, 2026, 5:35 PM CET
Sensorion Earnings Call Transcripts
Fiscal Year 2025
-
Gene therapy and small molecule programs are advancing, with key clinical milestones expected this year. Regulatory progress enables inclusion of younger patients, and financial runway extends to Q1 2026, with ongoing investor interest.
-
Sensorion is advancing gene therapies for hearing loss, with SENS-501 in Phase 1/2 showing early safety and behavioral improvements, and GJB2 progressing toward clinical trials. Strategic partnerships, a robust natural history network, and a focus on young patients differentiate its approach.